Charles river and vertex pharmaceuticals reach important milestone in cell therapy manufacturing collaboration

Wilmington, mass. & memphis, tenn.--(business wire)--charles river laboratories international, inc. (nyse: crl) today announced an important milestone in their strategic collaboration to manufacture casgevy™ (exagamglogene autotemcel [exa-cel]). casgevy is approved in some countries for certain eligible patients. the news follows charles river's memphis center of excellence passing back-to-back audits from both the u.s. food and drug administration (fda) and the health products regulatory autho.
CRL Ratings Summary
CRL Quant Ranking